<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672369</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI939A102(Ib)</org_study_id>
    <nct_id>NCT04672369</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC</brief_title>
  <official_title>An Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, phase I clinical study to evaluate the efficacy, tolerability&#xD;
      and safety of recombinant fully human anti-TIGIT antibody (IBI939) in combination with&#xD;
      recombinant fully human anti-programmed cell death receptor 1 (PD-1) antibody (sintilimab) in&#xD;
      subjects with advanced lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 6, 2021</start_date>
  <completion_date type="Anticipated">October 9, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 6, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate(ORR)</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of subjects with complete response(CR) or partial response(PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>The time from randomization to the first occurrence of objective disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>6 months</time_frame>
    <description>The time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of subjects with complete response (CR), partial response (PR), or stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>6 months</time_frame>
    <description>The time from the first documented objective tumor response(CR or PR) to objective disease progression (PD) or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Objective Response(TTR)</measure>
    <time_frame>6 months</time_frame>
    <description>Time from randomization to first objective tumor response (CR or PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration (Cmin)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL), 12. volume of distribution (V)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Advanced Lung Cancer</condition>
  <arm_group>
    <arm_group_label>IBI939 in combination with Sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sintilimab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI939</intervention_name>
    <description>IBI939 injection</description>
    <arm_group_label>IBI939 in combination with Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Sintilimab injection</description>
    <arm_group_label>IBI939 in combination with Sintilimab</arm_group_label>
    <arm_group_label>sintilimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed the Informed Consent Form;&#xD;
&#xD;
          2. Male or female ≥ 18 and≤75 years of age;&#xD;
&#xD;
          3. Life expectancy ≥ 12 weeks;&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score is 0 or 1&#xD;
&#xD;
          5. Have at least 1 lesion (not previously irradiated) with an accurately measured longest&#xD;
             diameter ≥ 10 mm by computed tomography (CT) or magnetic resonance imaging (MRI)&#xD;
             (intravenous contrast agent is preferred) at baseline (except lymph nodes which must&#xD;
             have short axis ≥ 15 mm) according to RECIST V1.1 and lesions amenable to repeated&#xD;
             accurate measurements.&#xD;
&#xD;
          6. Histologically or cytologically confirmednon-small cell lung cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous exposure to immune-mediated therapy; previous use of antitumor vaccine;&#xD;
&#xD;
          2. Received the last anti-tumor therapy within 4 weeks prior to the first dose of study&#xD;
             drug;&#xD;
&#xD;
          3. Received any investigational agent within 4 weeks prior to the first dose of study&#xD;
             drug;&#xD;
&#xD;
          4. Received systemic treatment with Chinese herbal medicine indicated for cancer or drugs&#xD;
             used for immunoregulation (including thymosin, interferon, interleukin, except for&#xD;
             local use for pleural effusion) within 2 weeks before the first dose;&#xD;
&#xD;
          5. Are participating in another interventional clinical study, or observational&#xD;
             (non-interventional) clinical study or in the follow-up phase of an interventional&#xD;
             study;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Cheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jilin Province Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pu Li</last_name>
    <phone>0512-69566088</phone>
    <email>pu.li@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jilin Province Cancer Hospital</name>
      <address>
        <city>Jilin</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ying Cheng, M.D.</last_name>
      <phone>0431-80596315</phone>
      <email>jl.cheng@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 13, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

